Kenneth Cornetta
Overview
Explore the profile of Kenneth Cornetta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
2155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cornetta K, Lin T, Tao H, Huang J, Piskorowski J, Wilcox P, et al.
J Virol Methods
. 2024 Jun;
329:114988.
PMID: 38908550
We evaluated the use of the Product Enhanced Reverse Transcriptase (PERT) assay as a means of detecting virus in retroviral vectors products pseudotyped with Gibbon Ape Leukemia Virus (GALV) and...
2.
Doxzen K, Adair J, Fonseca Bazzo Y, Bukini D, Cornetta K, Dalal V, et al.
Sci Transl Med
. 2024 May;
16(746):eadn1902.
PMID: 38718130
Gene therapies are designed to address the root cause of disease. As scientific understanding of disease prevention, diagnosis, and treatment improves in tandem with technological innovation, gene therapies have the...
3.
Elias H, Kisembe E, Nyariki S, Kiplimo I, Amisi J, Boit J, et al.
BMC Palliat Care
. 2024 Apr;
23(1):97.
PMID: 38605309
Objectives: Existing literature suggests multiple potential roles for community health volunteers (CHVs) in the provision of palliative care (PC) in low- and middle-income countries. In Kenya the role of CHV...
4.
Cornetta K, Kay S, Urio F, Minja I, Mbugi E, Mgaya J, et al.
Mol Ther
. 2023 Aug;
31(9):2561-2565.
PMID: 37595584
There has been rapid growth in gene therapy development with an expanding list of approved clinical products. Several therapies are particularly relevant to patients in low- and middle-income countries. Moreover,...
5.
Cornetta K, Nyariki S, Manji I, Kiplimo I, Korir M, Muinga E, et al.
J Pain Symptom Manage
. 2023 Feb;
65(5):378-387.
PMID: 36773732
Context: Worldwide, most patients lack access to hospice services. Objectives: Assess the feasibility of telephone monitoring (Telehospice) in providing symptom management for patients discharged from a tertiary care hospital in...
6.
Cornetta K, Lin T, Pellin D, Kohn D
Mol Ther Methods Clin Dev
. 2023 Jan;
28:28-39.
PMID: 36588821
Integrating vectors are associated with alterations in cellular function related to disruption of normal gene function. This has been associated with clonal expansion of cells and, in some instances, cancer....
7.
Cornetta K, Yao J, House K, Duffy L, Adusumilli P, Beyer R, et al.
Mol Ther
. 2022 Dec;
31(3):801-809.
PMID: 36518078
The clinical impact of any therapy requires the product be safe and effective. Gammaretroviral vectors pose several unique risks, including inadvertent exposure to replication competent retrovirus (RCR) that can arise...
8.
Elias H, Dow L, Boit J, Asirwa C, Cornetta K
JCO Glob Oncol
. 2022 May;
8:e2200025.
PMID: 35594498
Purpose: Most people living with life-limiting illnesses in Kenya lack access to palliative care. Globally, palliative medicine is a growing specialty that equips clinicians with the training required to improve...
9.
Cornetta K, Bonamino M, Mahlangu J, Mingozzi F, Rangarajan S, Rao J
Mol Ther
. 2022 Apr;
30(6):2122-2129.
PMID: 35390542
Gene and cell therapies for a variety of life-limiting illnesses are under investigation, and a small number of commercial products have successfully obtained regulatory approval. The cost of treatment is...
10.
Tarus A, Cornetta K, Morogo D, Nyongesa J, Elias H, Boit J
J Pain Symptom Manage
. 2021 Aug;
63(1):71-77.
PMID: 34333098
Context: Breast cancer in Kenya is associated with a high mortality due to late stage disease at presentation and limited access to specialty care. Objectives: To understand the symptom burden...